New drug BL-B01D1 shows promise for tough cancers in early trial
NCT ID NCT05470348
First seen Oct 31, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This early-phase study tests a new drug called BL-B01D1 in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 36 adults aged 18 to 75 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University ShangHai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, China
Contact
Conditions
Explore the condition pages connected to this study.